Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinisoquin for VTE prevention in pancreatic cancer
NCT06861088Phase 3Recruiting
- Sponsor
- Quercis Pharma
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of isoquercitrin in venous thromboembolism (VTE), sponsored by Quercis Pharma. Primary endpoint: Effectiveness of Kinisoquin in prevention of thromboembolic events at 16 weeks. Started Dec 2025; status: recruiting.
02
Drugs
isoquercitrin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06861088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861088.